MET and hepatocellular carcinoma: Second-line therapies for advanced HCC that are intolerant to first-line treatment include Regorafenib, Cabozantinib, Sunitinib, Linifanib, Brivanib, Tivantinib, Donafenib, etc. which target tyrosine kinases, HGF-MET axis, and related pathways (108).